Disease course heterogeneity and OCT in multiple sclerosis
暂无分享,去创建一个
P Tewarie | J Killestein | A Petzold | L J Balk | C H Polman | C. Polman | P. Tewarie | B. Uitdehaag | J. Killestein | L. Balk | L. Balk | A. Petzold | Bmj Uitdehaag | C. Polman | B. Uitdehaag | Axel Petzold
[1] A. Compston,et al. Multiple sclerosis. , 2002, Lancet.
[2] J. Schuman,et al. Optical coherence tomography. , 2000, Science.
[3] M Rovaris,et al. MRI features of benign multiple sclerosis , 2009, Neurology.
[4] A J Thompson,et al. Diagnostic criteria for primary progressive multiple sclerosis: A position paper , 2000, Annals of neurology.
[5] Eliza M. Gordon-Lipkin,et al. Optical coherence tomography and disease subtype in multiple sclerosis , 2007, Neurology.
[6] R. Rudick,et al. Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.
[7] Lublin Fd,et al. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .
[8] Axel Petzold,et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis , 2010, The Lancet Neurology.
[9] M. Esiri,et al. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. , 2004, Brain : a journal of neurology.
[10] David H. Miller,et al. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. , 2007, Brain : a journal of neurology.
[11] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[12] A. Thompson,et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. , 1990, BMJ.
[13] S. A. Meyer,et al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness , 2011, Multiple sclerosis.
[14] Hans Lassmann,et al. Remyelination is extensive in a subset of multiple sclerosis patients. , 2006, Brain : a journal of neurology.
[15] J. Correale,et al. Benign Multiple Sclerosis: Does it exist? , 2012, Current Neurology and Neuroscience Reports.
[16] D. Goodin,et al. Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes , 2012, PloS one.
[17] David H. Miller,et al. Primary-progressive multiple sclerosis , 2007, The Lancet Neurology.
[18] F. Paul,et al. Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography , 2012, Multiple sclerosis international.
[19] F. Barkhof,et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.
[20] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[21] A. Thompson,et al. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis , 2004, Multiple sclerosis.
[22] J. De Keyser,et al. Benign course in multiple sclerosis: a review , 2006, Acta neurologica Scandinavica.
[23] C. Polman,et al. A dam for retrograde axonal degeneration in multiple sclerosis? , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[24] R. Hintzen,et al. Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry , 2010, Journal of Neurology.
[25] Massimiliano Calabrese,et al. Measurement and clinical effect of grey matter pathology in multiple sclerosis , 2012, The Lancet Neurology.
[26] David H. Miller,et al. Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis , 2004 .
[27] M. Freedman,et al. Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes , 2009, Journal of the Neurological Sciences.
[28] R. Bakshi,et al. Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. , 2010, Annals of neurology.
[29] M. Battaglini,et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.
[30] A. Thompson,et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.
[31] P. Albrecht,et al. Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography , 2012, Multiple sclerosis.
[32] M. Rovaris,et al. Magnetic resonance-based techniques for the study and management of multiple sclerosis. , 2003, British medical bulletin.
[33] S. A. Meyer,et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning , 2013, Neurology.
[34] David H. Miller,et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.
[35] Axel Petzold,et al. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment , 2012, PloS one.